论文部分内容阅读
在德国汉堡召开的第4届欧洲乳腺癌学术会议上,中国香港大学临床肿瘤系的副教授 WinnieYeo 博士报道的研究结果显示,抗病毒药拉米夫定(lamivudine)预防性治疗可有助于 HBV 阳性的乳腺癌患者在接受化疗期间防止乙肝病毒的再次活动。本项研究的负责人 Yao 博士介绍说,在发展中国家,约12％以上的乳腺癌患者携带体内 HBV病毒,这些患者在接受化学治疗期间,肝炎复发也处于高危险之中,因此必须制定科学的治疗策
At the 4th European Breast Cancer Symposium in Hamburg, Germany, Dr. Winnie Yeo, an associate professor of clinical oncology at the University of Hong Kong, China, reported that prophylactic treatment with the antiviral lamivudine could contribute to HBV positive Of breast cancer patients prevent reactivation of hepatitis B virus during chemotherapy. Dr. Yao, head of the study, said that in developing countries, more than 12% of breast cancer patients carry HBV in the body and these patients are at high risk of recurrent hepatitis during chemotherapy, and science must be developed Treatment strategy